PD-L1 Testing Explained: Assays, Scores and Limits
PD-L1 testing is usually an immunohistochemistry measurement, but the antibody clone, platform, tumour type and scoring algorithm matter. A percentage without those details is incomplete.
Quick Answer
PD-L1 testing is usually an immunohistochemistry measurement, but the antibody clone, platform, tumour type and scoring algorithm matter. A percentage without those details is incomplete.
What the Stain Measures
PD-L1 IHC assesses staining in a tested specimen. It does not directly measure every component of anti-tumour immunity or predict response with certainty.
Why Score Names Matter
Tumour proportion score, combined positive score and immune-cell algorithms use different cells and denominators. Assay-specific thresholds cannot be assumed interchangeable.
Key Takeaways
- ·Keep clone, score, cut-off and tumour type with the result.
- ·PD-L1 is one biomarker, not a complete immune profile.
- ·Clinical use depends on the relevant validated setting.
Put these genes in pathway context
Frequently asked questions
What is the key idea in PD-L1 Testing Explained: Assays, Scores and Limits?
PD-L1 testing is usually an immunohistochemistry measurement, but the antibody clone, platform, tumour type and scoring algorithm matter. A percentage without those details is incomplete.
What should be kept with the result or mechanism?
Keep clone, score, cut-off and tumour type with the result. PD-L1 is one biomarker, not a complete immune profile. Clinical use depends on the relevant validated setting.
References
Continue Reading
HIF-1α and Tumour Hypoxia: A Signalling Guide
2 min read
Tumour Mutational Burden: How TMB Is Measured
2 min read
B2M and MHC Class I Loss: Hiding From T Cells
3 min read
HLA Loss of Heterozygosity: Losing Half the Presentation Repertoire
3 min read
How Tumours Suppress T-Cell Activation: PD-1, PD-L1, and CTLA4 Checkpoint Signalling
4 min read
MSI-High vs TMB-High: Two Different Tumour Biomarkers
2 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
STAT3 has 20+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.